Trial Outcomes & Findings for A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (NCT NCT00845481)
NCT ID: NCT00845481
Last Updated: 2025-03-12
Results Overview
The Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
COMPLETED
PHASE2
24 participants
Baseline and 3 weeks
2025-03-12
Participant Flow
Participant milestones
| Measure |
Patients Treated
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants.
|
|---|---|
|
Overall Study
STARTED
|
24
|
|
Overall Study
COMPLETED
|
24
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
Baseline characteristics by cohort
| Measure |
Patients Treated
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants.
|
|---|---|
|
Age, Continuous
|
50.5 years
STANDARD_DEVIATION 9.6 • n=99 Participants
|
|
Age, Customized
<=18 years
|
0 participants
n=99 Participants
|
|
Age, Customized
Between 18 and 67 years
|
23 participants
n=99 Participants
|
|
Age, Customized
>=68 years
|
1 participants
n=99 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=99 Participants
|
|
Region of Enrollment
France
|
24 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet® Ointment
|
-5.15 Scores on a scale
Standard Error 1.31
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Betnovat® Ointment
|
-3.33 Scores on a scale
Standard Error 2.44
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Elocon Ointment
|
-4.50 Scores on a scale
Standard Error 1.74
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet Ointment Vehicle
|
-1.91 Scores on a scale
Standard Error 1.15
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Dermovat Ointment
|
-5.71 Scores on a scale
Standard Error 1.39
|
PRIMARY outcome
Timeframe: Baseline and 3 weeksThe Total Clinical Score is the sum of three psoriasis scores (redness, thickness, and scaliness) and will range from 0 (best) to 9 (worst)
Outcome measures
| Measure |
Patients Treated With Daivobet® Ointment
n=24 Participants
Treatments are given at the same time on different locations of the skin with psoriasis in the same group of participants. The treatment for this outcome measure is Daivobet® ointment
|
|---|---|
|
The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Diprosalic Ointment
|
-4.50 Scores on a scale
Standard Error 1.84
|
Adverse Events
Patients Treated
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee LEO retains the right to publish the results of this clinical trial
- Publication restrictions are in place
Restriction type: OTHER